Cuba Has Made At Least 3 Major Medical Innovations That We Need
By most measures, the United States' business-friendly environment has proven to be fertile for medical innovation. Compared to other countries, America has filed the most patents in the life sciences, is conducting most of the world's clinical trials and has published the most biomedical research. That's what makes the medical prominence of Cuba all the more surprising to those who view a free market as an essential driver of scientific discovery. Cuba is very poor, and yet the country has some of the healthiest, most long-lived residents in the world -- as well as a medical invention or two that could run circl...
Source: Science - The Huffington Post - March 15, 2016 Category: Science Source Type: news
Research points to why some colorectal cancers recur after treatment
(University of Texas M. D. Anderson Cancer Center) Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2015 Category: Cancer & Oncology Source Type: news
Research points to why some colorectal cancers recur after treatment
Cetuximab, marketed as Erbitux®, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 16, 2015 Category: Cancer & Oncology Source Type: news
Cetuximab Benefits Select Patients With Advanced Lung CancerCetuximab Benefits Select Patients With Advanced Lung Cancer
Adding cetuximab to chemotherapy failed to improve outcomes in the overall population of patients with non-small-cell lung cancer, but did confer a benefit in certain subgroups. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cetuximab Finds Niche in Non-Small Cell Lung Cancer (CME/CE)
(MedPage Today) -- Significant survival improvement in squamous, EGFR+ subgroup (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 13, 2015 Category: Geriatrics Source Type: news
Medtech approvals: FDA releases May 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in May 2015:
Summary of PMA Originals & Supplements Approved
Originals: 5
Supplements: 51
Summary of PMA Originals Under Review
Total Under Review: 55
Total Active: 26
Total On Hold: 29
Summary of PMA Supplements Under Review
Total Under Review: 547
Total Active: 379
Total On Hold: 168
Summary of All PMA Submissions
Originals: 1
Supplements: 62
Summary of PMA Supplement PMA Approval/Denial Decision Times
Number of Approvals: 51
Number of Denials: 0
Average Days Fr Receipt to Decision (Total Time): 109.5
FDA Time: 86.4 D...
Source: Mass Device - August 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news
Are Cetuximab Study Critics Acting Like Don Quixote?Are Cetuximab Study Critics Acting Like Don Quixote?
A group of investigators said the drug should not be used in a specific type of metastatic colorectal cancer. A group of critics disagrees. The argument continues. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Colorectal cancer: Second-line cetuximab active beyond progression in quadruple wild-type patients with mcrc
Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to new study results. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 4, 2015 Category: Science Source Type: news
Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC
(European Society for Medical Oncology) Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to study results presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 4, 2015 Category: Cancer & Oncology Source Type: news
New Immune Therapies Show Major Promise In Shrinking Cancer Tumors
CHICAGO (AP) — For the first time, a major study shows that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer.
These newer kinds of drugs have transformed treatment of melanoma, the deadliest kind of skin cancer. Studies presented at a conference Friday suggest these "immune therapies" can play a broader role in more common cancers, including lung, liver, colon and head and neck.
Doctors also may have found a way to help predict which patients would respond best to one of these newer treatments, according to research presented at the Chicago meeting....
Source: Science - The Huffington Post - June 1, 2015 Category: Science Source Type: news
A better biomarker to predict cetuximab response in CRC patients
(InSilico Medicine, Inc.) Scientists at Insilico Medicine, Inc. and Champions Oncology, Inc. have successfully demonstrate a method to predict response to cetuximab in patients with colorectal cancer using OncoFinder pathway activation strength. The study identified a novel prognostic marker in colorectal cancer treated with cetuximab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 7, 2015 Category: Global & Universal Source Type: news
Erbitux Colorectal Cancer Treatment Market Analysis and Forecast to...
This report focuses on the current treatment landscape, unmet needs, current pipeline and...(PRWeb December 23, 2014)Read the full story at http://www.prweb.com/releases/erbitux-colorectal-cancer/market-analysis-to-2023/prweb12413234.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 25, 2014 Category: Pharmaceuticals Source Type: news
JCO Withdraws Editorial on Cetuximab for Metastatic CRCJCO Withdraws Editorial on Cetuximab for Metastatic CRC
The editorial critiqued the negative findings of a major clinical trial and discouraged clinicians from following the trial investigators' conclusion. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 25, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Three drugs may be better than one for certain patients with advanced colorectal cancer
(ECCO-the European CanCer Organisation) Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results, reported at the 26th EORTC-NCI-AACR Symposium, from a multi-center clinical trial suggest that the cancer may respond to a combination of three targeted drugs: encorafenib, cetuximab and alpelisib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2014 Category: Global & Universal Source Type: news
Tomotherapy and Cetuximab for Unresectable SCC of the SkinTomotherapy and Cetuximab for Unresectable SCC of the Skin
This case report describes a novel approach to unresectable squamous cell carcinoma, utilizing radiation therapy in conjunction with an EGFR-inhibitor. BMC Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 17, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
